Zkusit zdarma
ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc.

ORIC
Cena:
$ 8.32
-0.14 (-1.65%)
Valuace
70
Růst
33
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

16:40 21-05-2026

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

17:33 19-05-2026

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

20:15 14-05-2026

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

17:41 12-05-2026

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest...

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

16:05 04-05-2026

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 g...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16:30 01-05-2026

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

22:40 30-04-2026

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

17:24 28-04-2026

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC

16:40 21-04-2026

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve...

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

16:05 17-04-2026

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

10:00 16-04-2026

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor...

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

22:58 15-04-2026

LOS ANGELES--(BUSINESS WIRE)---- $ORIC--ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

17:01 14-04-2026

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve...

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

8:06 06-04-2026

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16:30 03-04-2026

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, ...

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Analyst Downgrade

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Analyst Downgrade

1:09 02-04-2026

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report) shares gapped down prior to trading on W...

What's Behind The Drop In Oric Pharmaceuticals Stock Today?

What's Behind The Drop In Oric Pharmaceuticals Stock Today?

11:08 01-04-2026

Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announc...

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

4:32 01-04-2026

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial...

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

16:05 31-03-2026

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 gl...

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

8:30 27-03-2026

Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET Company to ho...

close

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

06-02-2026
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, FEB. 06, 2026 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

05-02-2026
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, FEB. 05, 2026 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS PROVIDES OPERATIONAL HIGHLIGHTS FOR 2025 AND ANTICIPATED UPCOMING MILESTONES

12-01-2026
ANNOUNCED RINZIMETOSTAT (ORIC-944) PHASE 1B DATA THAT CONTINUE TO DEMONSTRATE POTENTIAL BEST-IN-CLAS...
Více zde

ORIC® PHARMACEUTICALS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

06-01-2026
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, JAN. 06, 2026 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS PRESENTS POTENTIAL BEST-IN-CLASS PROFILE FOR ENOZERTINIB WITH ROBUST SYSTEMIC AND CNS ACTIVITY IN 1L AND 2L NSCLC PATIENTS WITH EGFR EXON 20 MUTATIONS AT THE ESMO ASIA CONGRESS 2025

05-12-2025
HIGHLY DIFFERENTIATED 1L PRELIMINARY SYSTEMIC ACTIVITY OF 67% ORR AND 100% INTRACRANIAL ORR (BY BICR...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-12-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, DEC. 05, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS PRESENTS ENOZERTINIB DATA IN NSCLC PATIENTS WITH HER2 EXON 20 MUTATIONS AT THE ESMO ASIA CONGRESS 2025

05-12-2025
SYSTEMIC ACTIVITY OF 35% ORR IN 2L+ PATIENTS, INCLUDING IN PATIENTS WITH ACTIVE BRAIN METASTASES MAN...
Více zde

ORIC® PHARMACEUTICALS PRESENTS POTENTIAL BEST-IN-CLASS PROFILE FOR ENOZERTINIB WITH ROBUST SYSTEMIC AND CNS ACTIVITY IN 1L AND PREVIOUSLY TREATED NSCLC PATIENTS WITH EGFR ATYPICAL MUTATIONS AT THE ESMO ASIA CONGRESS 2025

04-12-2025
HIGHLY DIFFERENTIATED 1L EGFR PACC PRELIMINARY SYSTEMIC ACTIVITY OF 80% ORR AND 100% INTRACRANIAL OR...
Více zde

ORIC® PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) LATE-BREAKING ORAL PRESENTATIONS IN EGFR ATYPICAL AND EGFR EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025

03-12-2025
COMPANY TO HOST A CONFERENCE CALL AND WEBCAST ON SATURDAY, DECEMBER 6, 2025, AT 8:00 PM ET COMPANY T...
Více zde

ORIC® PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) POSTER PRESENTATION IN HER2 EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025

01-12-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

24-11-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 24, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CLINICAL AND OPERATIONAL UPDATES

13-11-2025
ANNOUNCED COMPLETION OF DOSE EXPLORATION PORTION OF ORIC-944 PHASE 1B CLINICAL TRIAL AND PRESENTED D...
Více zde

ORIC® PHARMACEUTICALS ANNOUNCES COMPLETION OF DOSE EXPLORATION PORTION OF ORIC-944 PHASE 1B CLINICAL TRIAL AND CONTINUES TO DEMONSTRATE POTENTIAL BEST-IN-CLASS EFFICACY AND SAFETY

13-11-2025
EFFICACY DATA REMAIN CONSISTENT WITH PRIOR DISCLOSURE AND CONTINUE TO DEMONSTRATE BROAD AND DEEP PSA...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

07-11-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 07, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS ANNOUNCES PUBLICATION IN CANCER RESEARCH ON THE DISCOVERY AND DEVELOPMENT OF ENOZERTINIB, A HIGHLY SELECTIVE, BRAIN-PENETRANT EGFR INHIBITOR

06-11-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 06, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

04-11-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS PRESENTED PRECLINICAL DATA AT THE EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS SUPPORTING BEST-IN-CLASS POTENTIAL OF ORIC-944 TO TREAT PATIENTS WITH PROSTATE CANCER AND OTHER SOLID TUMORS

27-10-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, OCT. 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-09-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, SEPT. 05, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, ...
Více zde

ORIC® PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

27-08-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS EXPANDS LEADERSHIP TEAM WITH THE APPOINTMENT OF KEVIN BRODBECK AS CHIEF TECHNICAL OFFICER

18-08-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 18, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL UPDATES

12-08-2025
REPORTED POTENTIALLY BEST-IN-CLASS CLINICAL EFFICACY AND SAFETY DATA FROM ONGOING PHASE 1B TRIAL OF ...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

01-08-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 01, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-07-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

06-06-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, JUNE 06, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, I...
Více zde

ORIC® PHARMACEUTICALS ANNOUNCES POTENTIALLY BEST-IN-CLASS PRELIMINARY EFFICACY AND SAFETY DATA FROM ONGOING PHASE 1B TRIAL OF ORIC-944 IN COMBINATION WITH AR INHIBITORS FOR THE TREATMENT OF PATIENTS WITH MCRPC

28-05-2025
BROAD AND DEEP PSA RESPONSES ACHIEVED, WITH 59% PSA50 RESPONSE RATE (CONFIRMED RATE OF 47%, AND ONE ...
Více zde

ORIC® PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

27-05-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, MAY 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, IN...
Více zde

ORIC® PHARMACEUTICALS TO PRESENT INITIAL DATA FROM PHASE 1B TRIAL OF ORIC-944 IN COMBINATION WITH ANDROGEN RECEPTOR INHIBITORS IN PATIENTS WITH MCRPC

27-05-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, MAY 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, IN...
Více zde

ORIC® PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL UPDATES

05-05-2025
ANNOUNCED FOCUSED REGISTRATIONAL CLINICAL DEVELOPMENT PLANS FOR LEAD PROGRAMS, EXTENDED CASH RUNWAY,...
Více zde

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-05-2025
SOUTH SAN FRANCISCO CALIF. AND SAN DIEGO, MAY 02, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC...
Více zde

ORIC® PHARMACEUTICALS PRESENTS PRECLINICAL DATA TO SUPPORT THE POTENTIAL OF ORIC-944 AS A BEST-IN-CLASS PRC2 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

28-04-2025
SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, ...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-12-08 00:00:008-KStáhnout
2025-11-13 00:00:008-KStáhnout
2025-11-13 00:00:0010-QStáhnout
2025-08-12 01:00:008-KStáhnout
2025-08-12 01:00:0010-QStáhnout
2025-08-12 00:00:008-KStáhnout
2025-08-12 00:00:0010-QStáhnout
2025-06-13 01:00:008-KStáhnout
2025-06-13 00:00:008-KStáhnout
2025-05-28 01:00:008-KStáhnout
2025-05-28 00:00:008-KStáhnout
2025-05-05 01:00:008-KStáhnout
2025-05-05 01:00:0010-QStáhnout
2025-05-05 00:00:008-KStáhnout
2025-05-05 00:00:0010-QStáhnout
2025-03-14 00:00:008-KStáhnout
2025-03-13 23:00:008-KStáhnout
2025-02-25 00:00:008-KStáhnout
2025-02-24 23:00:008-KStáhnout
2025-02-18 00:00:008-KStáhnout
2025-02-18 00:00:0010-KStáhnout
2025-02-17 23:00:008-KStáhnout
2025-02-17 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:008-KStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-08-12 01:00:008-KStáhnout
2024-08-12 01:00:0010-QStáhnout
2024-08-12 00:00:008-KStáhnout
2024-08-12 00:00:0010-QStáhnout
2024-06-14 01:00:008-KStáhnout
2024-06-14 00:00:008-KStáhnout
2024-05-06 01:00:008-KStáhnout
2024-05-06 01:00:0010-QStáhnout
2024-05-06 00:00:008-KStáhnout
2024-05-06 00:00:0010-QStáhnout
2024-03-29 00:00:008-KStáhnout
2024-03-28 23:00:008-KStáhnout
2024-03-11 00:00:008-KStáhnout
2024-03-11 00:00:0010-KStáhnout
2024-03-10 23:00:008-KStáhnout
2024-03-10 23:00:0010-KStáhnout
2024-01-22 00:00:008-KStáhnout
2024-01-21 23:00:008-KStáhnout
2024-01-09 00:00:008-KStáhnout
2024-01-08 23:00:008-KStáhnout
2023-12-11 00:00:008-KStáhnout
2023-12-10 23:00:008-KStáhnout
2023-11-06 00:00:008-KStáhnout
2023-11-06 00:00:0010-QStáhnout
2023-11-05 23:00:008-KStáhnout
2023-11-05 23:00:0010-QStáhnout
2023-10-23 01:00:008-KStáhnout
2023-10-23 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-06-27 01:00:008-KStáhnout
2023-06-27 00:00:008-KStáhnout
2023-06-15 01:00:008-KStáhnout
2023-06-15 00:00:008-KStáhnout
2023-05-08 01:00:008-KStáhnout
2023-05-08 01:00:0010-QStáhnout
2023-05-08 00:00:008-KStáhnout
2023-05-08 00:00:0010-QStáhnout
2023-03-24 00:00:008-KStáhnout
2023-03-23 23:00:008-KStáhnout
2023-03-16 00:00:008-KStáhnout
2023-03-16 00:00:0010-KStáhnout
2023-03-15 23:00:008-KStáhnout
2023-03-15 23:00:0010-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-21 00:00:008-KStáhnout
2022-12-20 23:00:008-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-07 00:00:0010-QStáhnout
2022-11-06 23:00:008-KStáhnout
2022-11-06 23:00:0010-QStáhnout
2022-08-11 01:00:008-KStáhnout
2022-08-11 01:00:0010-QStáhnout
2022-08-11 00:00:008-KStáhnout
2022-08-11 00:00:0010-QStáhnout
2022-06-21 01:00:008-KStáhnout
2022-06-21 00:00:008-KStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 01:00:0010-QStáhnout
2022-05-09 00:00:008-KStáhnout
2022-05-09 00:00:0010-QStáhnout
2022-03-21 00:00:008-KStáhnout
2022-03-21 00:00:0010-KStáhnout
2022-03-20 23:00:008-KStáhnout
2022-03-20 23:00:0010-KStáhnout
2022-03-04 00:00:008-KStáhnout
2022-03-03 23:00:008-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-08 00:00:008-KStáhnout
2021-11-08 00:00:0010-QStáhnout
2021-11-07 23:00:008-KStáhnout
2021-11-07 23:00:0010-QStáhnout
2021-10-07 01:00:008-KStáhnout
2021-10-07 00:00:008-KStáhnout
2021-08-18 01:00:008-KStáhnout
2021-08-18 00:00:008-KStáhnout
2021-08-16 01:00:008-KStáhnout
2021-08-16 00:00:008-KStáhnout
2021-08-10 01:00:008-KStáhnout
2021-08-10 01:00:0010-QStáhnout
2021-08-10 00:00:008-KStáhnout
2021-08-10 00:00:0010-QStáhnout
2021-07-12 01:00:008-KStáhnout
2021-07-12 00:00:008-KStáhnout
2021-07-08 01:00:008-KStáhnout
2021-07-08 00:00:008-KStáhnout
2021-06-21 01:00:008-KStáhnout
2021-06-21 00:00:008-KStáhnout
2021-05-06 01:00:008-KStáhnout
2021-05-06 01:00:0010-QStáhnout
2021-05-06 00:00:008-KStáhnout
2021-05-06 00:00:0010-QStáhnout
2021-03-23 00:00:008-KStáhnout
2021-03-23 00:00:0010-KStáhnout
2021-03-22 23:00:008-KStáhnout
2021-03-22 23:00:0010-KStáhnout
2021-01-11 00:00:008-KStáhnout
2021-01-10 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-10-19 01:00:008-KStáhnout
2020-10-19 00:00:008-KStáhnout
2020-08-05 01:00:008-KStáhnout
2020-08-05 01:00:0010-QStáhnout
2020-08-05 00:00:008-KStáhnout
2020-08-05 00:00:0010-QStáhnout
2020-06-10 01:00:008-KStáhnout
2020-06-10 00:00:008-KStáhnout
2020-05-20 01:00:008-KStáhnout
2020-05-20 01:00:0010-QStáhnout
2020-05-20 00:00:008-KStáhnout
2020-05-20 00:00:0010-QStáhnout
2020-04-28 01:00:008-KStáhnout
2020-04-28 00:00:008-KStáhnout
preloader